and
             Pharmacy sections.

        Exclusion Criteria:

          1. Does not meet inclusion criteria.

          2. Participant unable or unwilling to provide informed consent.

          3. Participant has any of the symptoms above or screens positive for possible COVID-19
             disease.

          4. Participant is currently enrolled in a study to evaluate an investigational drug.

          5. Vulnerable populations deemed inappropriate for study by the site Principal
             Investigator.

          6. The participant has a known allergy/hypersensitivity or has a medication or
             co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or
             renal failure) that prevents the use of HCQ (see pharmacy section).

          7. The participant is a woman of childbearing age whose pregnancy status is unknown and
             is not willing to use 2 methods of contraception.

          8. The participant is pregnant or nursing.

          9. The participant was diagnosed with retinopathy prior to study entry.

         10. The participant has a diagnosis of porphyria prior to study entry.

         11. The participant has renal failure with a creatinine clearance of <10 ml/min,
             pre-dialysis or requiring dialysis.

         12. The Participant has a family history of Sudden Cardiac Death.

         13. The participant is currently on diuretic therapy.

         14. The participant has a history of known Prolonged QT Syndrome.

         15. The participant is already taking any of the following medications: Abiraterone
             acetate, Agalsidase, Amodiaquine, Azithromycin, Conivaptan, Dabrafenib, Dacomitinib,
             Dapsone (Systemic), Digoxin, Enzalutamide, Fusidic Acid (Systemic), Idelalisib,
             Lanthanum, Lumefantrine, Mefloquine, Mifepristone, Mitotane, Pimozide, QT-prolonging
             Agents, Stiripentol).
      